PSYENCE BIOMEDICAL LTD. (PBM) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does PSYENCE BIOMEDICAL LTD. Do?
PSYENCE BIOMEDICAL LTD. (PBM) is a micro-cap company in the Healthcare sector, operating within the Pharmaceutical Products industry. The stock has a market capitalization of $5M, making it a notable participant in its sector. Investors researching PBM stock will find a comprehensive, data-driven analysis below covering valuation, profitability, growth, dividends, and peer comparisons for the Pharmaceutical Products space.
PSYENCE BIOMEDICAL LTD. (PBM) Stock Rating — Reduce (April 2026)
As of April 2026, PSYENCE BIOMEDICAL LTD. receives a Reduce rating with a composite score of 35.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PBM ranks #2,306 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PSYENCE BIOMEDICAL LTD. ranks #274 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
PBM Stock Price and 52-Week Range
PSYENCE BIOMEDICAL LTD. (PBM) currently trades at $2.55. The stock gained $0.05 (2.0%) in the most recent trading session. The 52-week high for PBM is $12.64, which means the stock is currently trading -79.8% from its annual peak. The 52-week low is $0.37, putting the stock 595.6% above its annual trough. Recent trading volume was 53K shares, suggesting relatively thin trading activity.
Is PBM Overvalued or Undervalued? — Valuation Analysis
PSYENCE BIOMEDICAL LTD. (PBM) carries a value factor score of 36/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 0.51x, compared to the Healthcare sector average of 23.63x — a discount of 98%. The price-to-book ratio stands at 0.85x, versus the sector average of 2.75x. On an enterprise value basis, PBM trades at -0.11x EV/EBITDA, versus 6.34x for the sector.
At current multiples, PSYENCE BIOMEDICAL LTD. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
PSYENCE BIOMEDICAL LTD. Profitability — ROE, Margins, and Quality Score
PSYENCE BIOMEDICAL LTD. (PBM) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 60.2%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 55.3% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
PBM Debt, Balance Sheet, and Financial Health
PSYENCE BIOMEDICAL LTD. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $6M.
PBM has a beta of 0.99, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for PSYENCE BIOMEDICAL LTD. is 21/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
PSYENCE BIOMEDICAL LTD. Revenue and Earnings History — Quarterly Trend
In TTM 2026, PSYENCE BIOMEDICAL LTD. reported revenue of $-483,530 and earnings per share (EPS) of $5.24. Net income for the quarter was $1M. Operating income came in at $-4M.
In FY 2025, PSYENCE BIOMEDICAL LTD. reported revenue of $-483,530 and earnings per share (EPS) of $5.24. Net income for the quarter was $1M. Revenue grew -499.9% year-over-year compared to FY 2024. Operating income came in at $-4M.
In FY 2024, PSYENCE BIOMEDICAL LTD. reported revenue of $-80,603 and earnings per share (EPS) of $-4674.25. Net income for the quarter was $-51M. Revenue grew -1046.7% year-over-year compared to FY 2023. Operating income came in at $-3M.
In FY 2023, PSYENCE BIOMEDICAL LTD. reported revenue of $-7,029. Net income for the quarter was $-3M. Operating income came in at $-3M.
Over the past 4 quarters, PSYENCE BIOMEDICAL LTD. has experienced revenue contraction from $-7,029 to $-483,530. Investors analyzing PBM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
PBM Dividend Yield and Income Analysis
PSYENCE BIOMEDICAL LTD. (PBM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
PBM Momentum and Technical Analysis Profile
PSYENCE BIOMEDICAL LTD. (PBM) has a momentum factor score of 61/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 5/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.
PBM vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, PSYENCE BIOMEDICAL LTD. (PBM) ranks #274 out of 838 stocks based on the Blank Capital composite score. This places PBM in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing PBM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PBM vs S&P 500 (SPY) comparison to assess how PSYENCE BIOMEDICAL LTD. stacks up against the broader market across all factor dimensions.
PBM Next Earnings Date
No upcoming earnings date has been announced for PSYENCE BIOMEDICAL LTD. (PBM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy PBM? — Investment Thesis Summary
The quantitative profile for PSYENCE BIOMEDICAL LTD. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 36/100 indicates premium valuation. Price momentum is positive at 61/100, suggesting the trend favors buyers. High volatility (stability score 21/100) increases portfolio risk.
In summary, PSYENCE BIOMEDICAL LTD. (PBM) earns a Reduce rating with a composite score of 35.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PBM stock.
Related Resources for PBM Investors
Explore more research and tools: PBM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PBM head-to-head with peers: PBM vs AZN, PBM vs SLGL, PBM vs VMD.